Dr. Daniel C. Smith has been appointed chief scientific officer at Cobra Biologics, with responsibility for developing scientific excellence across the group and enhancing Cobra’s DNA, virus, microbial and mammalian proteins R&D platforms.
Dr. Smith joins the company from HealthTech & Medicines Knowledge Transfer Network (KTN), where he served as a Knowledge Transfer Manager on the bioProcessUK team, responsible for driving the innovation agenda for biologics bioprocessing in the UK. Previously, Dr. Smith held a variety of roles progressing from senior scientist to commercial scientific development manager, responsible for developing the strategy for customer’s projects, and maintaining scientific oversight of Cobra’s R&D projects.
Peter Coleman, chief executive officer at Cobra Biologics, said, “This is a significant appointment for Cobra and I am personally very pleased that Dan has decided to return to Cobra as our new CSO. He has a tremendous enthusiasm for science and its application in our industry and from working with him previously, I firmly believe he has experience and ability to further establish Cobra as a leading scientific organization.”